Svetomir N. Markovic
Mayo Clinic
428 Papers
2.5K Citations
Svetomir N. Markovic is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Medicine & Melanoma. The author has an hindex of 62, co-authored 392 publications. Previous affiliations of Svetomir N. Markovic include University of Iowa & University of Rochester.
Chat about Author
Papers
Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials
Edward L. Korn,P. Y. Liu,Sandra J. Lee,Judith Anne W. Chapman,Donna Niedzwiecki,Vera J. Suman,James J. Moon,Vernon K. Sondak,Michael B. Atkins,Elizabeth Eisenhauer,Wendy R. Parulekar,Svetomir N. Markovic,Scott Saxman,John M. Kirkwood +13 more
TL;DR: In this paper, the authors evaluated historical data from cooperative group phase II trials to attempt to develop benchmarks for overall survival (OS) and progression-free survival (PFS) as reference points for future phase II clinical trials.
715
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.
Yucai Wang,Shouhao Zhou,Shouhao Zhou,Fang Yang,Xinyue Qi,Xin Wang,Xiaoxiang Guan,Xiaoxiang Guan,Chan Shen,Narjust Duma,Jesus Vera Aguilera,Ashish V. Chintakuntlawar,Katharine A. Price,Julian R. Molina,Lance C. Pagliaro,Thorvardur R. Halfdanarson,Axel Grothey,Axel Grothey,Svetomir N. Markovic,Grzegorz S. Nowakowski,Stephen M. Ansell,Michael L. Wang +21 more
TL;DR: Different PD-1 and PD-L1 inhibitors appear to have varying treatment-related adverse events; a comprehensive summary of the incidences of treatment- related adverse events in clinical trials provides an important guide for clinicians.
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma.
Luis F. Porrata,Morie A. Gertz,David J. Inwards,Mark R. Litzow,Martha Q. Lacy,Ayalew Tefferi,Dennis A. Gastineau,Angela Dispenzieri,Stephen M. Ansell,Ivana N. Micallef,Susan Geyer,Svetomir N. Markovic +11 more
TL;DR: ALC is correlated with clinical outcome and requires further study, and Multivariate analysis demonstrated day 15 ALC to be an independent prognostic indicator for OS and PFS rates for both groups of patients.
310
Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents.
Shernan G. Holtan,Douglas J. Creedon,Paul Haluska,Svetomir N. Markovic +3 more
- 01 Nov 2009
TL;DR: In this article, a review summarizes the similarities between growth and immune privilege in cancer and pregnancy and identifies areas for further investigation, and the knowledge gained from analyzing similarities and differences between the physiologic state of pregnancy and the pathology of cancer could lead to identification of new potential targets for cancer therapeutic agents.
303
Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies.
Justin C. Kao,Bing Liao,Svetomir N. Markovic,Christopher J. Klein,Elie Naddaf,Nathan P. Staff,Teerin Liewluck,Julie E. Hammack,Paola Sandroni,Heidi D. Finnes,Michelle M Mauermann +10 more
TL;DR: Investigating the frequency, clinical spectrum, and optimum treatment approach to neurological complications associated with anti–PD-1 therapy found a diverse phenotype, with more frequent neuromuscular complications.
278